Articles On Immutep (ASX:IMM)

Highlights Life360 (360), Codan Limited (CDA) and Immutep Limited (IMM) report robust revenue and margin expansion Technology sector advances on benchmarks tracked by the ASX 200, S&P/ASX All Technology Index Operational...

ASX posts 0.22pc gains, recovering from dip earlier in the day Xero brings big profit and revenue gains in quarterly report, lifting stock 4.7pc Insurance Australia surges 5.7pc on Royal Automobile Club of Western Australia deal   It was...

Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The a...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Immutep Ltd (ASX: IMM) shares are catching the eye on Thursday. In morning trade, the ASX 300 stock is up 11% to 31 cents. Why is this ASX 300 stock rocketing? Investors have been bidding the late-stage immunotherapy company's shares higher...

Highlights ERW reports high-grade silver surface samples using XRF analysis IMM involved in cancer treatment research combining multiple therapies LLC explores international development projects with UK-based Crown Estate...

The ASX200 is set to open nearly three quarters of a percent lower today (-0.41%), echoing a mixed performance on Wall Street. Listen to the HotCopper podcast for in-depth discussions and insights on all thebiggest headlines from through...

Highlights ASX 200 saw mixed sector performance with Energy and Real Estate leading gains. Immutep (IMM) and Carnegie Clean Energy (CCE) featured in Health and Energy developments. Declines recorded by Platinum Asset Managem...

Highlights Gold miners led gains as the ASX All Ords Gold index advanced, lifting the broader materials space Energy and tech sectors showed strength, defying broader market softness Small cap momentum driven by copper and g...

The ASX200 closed slightly down 0.08% at 8,151 points. Energy and Real Estate were the best performing sectors, up 0.8%, followed by Materials, Utilities, Telecommunication and Discretionary – all up around 0.6%. Health Care was the w...

ASX Gold Index leads gains, up more than 4pc Energy sector in the green despite 2pc oil price fall Tech index bucks Nasdaq’s trend to rise 0.8pc   It’s been a rollercoaster of a day on the ASX, with the bourse swinging wildly up and down...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

The All Ordinaries Index (ASX: XAO) is down 0.3% today, but don't blame this surging ASX All Ords share. The soaring stock in question is clinical-stage biotech company Immutep Ltd (ASX: IMM). Immutep shares closed on Friday at 27 cents ap...

Highlights S&P/ASX 200 and All Ordinaries lift following Wall Street momentum New World Resources Ltd (ASX:NWC) and Pioneer Lithium Ltd (ASX:PLN) report progress in resource exploration Immutep Ltd (ASX:IMM) reveals new...

The ASX200 is set to open nearly a third of a percent higher today (0.27%) echoing Wall Street’s positive end to the week, driven by a strong jobs report and indications that trade tensions might be easing. Listen to the HotCopper podcas...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Immutep Ltd (ASX:IMM) has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial – the final stage of clinical study before the company eventually takes final efficacy results to regulators. Listen to the HotCo...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

  Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

Immutep Ltd (ASX:IMM) has reported a small-scale conceptual safety test among 49 patients using flagship drug IMP761 has seen no adverse effects. Despite this, shares were down nearly -3% after twenty minutes of Tuesday trade. The data r...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha...

Here are 10 stocks rated ‘Strong Buy’ by brokers Mining, biotech and energy stocks top list Life360, West African Resources lead picks   The list of stocks below is compiled based on a report from Commsec, which averages the recommendatio...

S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) is charging higher today. Shares in the clinical-stage biotech company closed yesterday trading for 35.5 cents. In earlier trade, shares were changing hands for 38....

Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024. The trial combines the company’s lead drug candidate eftilagimod alpha (efti) with Merck & Co’s...

Immutep (ASX:IMM) has announced the initiation of its TACTI-004 Phase III clinical trial, which aims to evaluate the efficacy of its lead immunotherapy candidate, eftilagimod alfa ("efti"), in treating first-line metastatic non-small cell l...

ASX All Ords stock Immutep Ltd (ASX: IMM) has underperformed the All Ordinaries Index (ASX: XAO) this past year. Over the last 12 months, Immutep shares have gained just under 5%. That compares to an almost 18% gain posted by the All Ords o...

The ASX 200 is expected to dip into the red this Friday, with futures down 0.27% as the booming 2024 Santa rally faces its first early trough. Part of the reason for red tickers across the Aussie bourse in Friday futures was a pause on W...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases a...

Immutep Ltd (ASX: IMM) shares ended the week on a disappointing note. The small cap ASX biotechnology share fell 3% to finish the session at 33 cents. But its shares may not be trading at those levels for long if one leading broker is to be...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on prelimin...

Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, whic...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck In this week's Weekly Insights:-Mate, Where Have The Profits Gone?-Al...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Immutep (ASX:IMM) has released its annual report, detailing significant progress over the past year with its lead immunotherapy candidate eftilagimod alpha (efti). This drug is designed to activate the body’s immune system to better recogni...

  To register for Friday's webinar click here. Immutep Limited (ASX:IMM) has fully recruited participants for Part A of its Phase I study evaluating IMP761, a novel LAG-3 immunotherapy. The single-dose, placebo-controlled trial has been com...

With the gold price trading around record highs, a number of ASX 200 gold shares have been rallying strongly this year. This has seen the S&P/ASX All Ordinaries Gold index rise 22% since the start of the year. But if you thought you wer...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Cettire Ltd (ASX: CTT) shares are catching the eye with a very strong gain on Tuesday. At the time of writing, the ASX All Ordinaries stock is up 48% to $1.98. Though, the online luxury products retailer's shares remain down by 60% from the...

Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates. The incentive – worth €2,194,918 – was provided under t...

The ASX200 is expected to open 0.12% lower today, despite strong gains on Wall Street. Investors in Australia are awaiting the Reserve Bank of Australia's (RBA) announcement on interest rates, with a decision due later today.   In the U.S....

The ASX200 is set to open 0.12% lower today, despite strong performances on Wall Street, as Australian investors await a rate cut decision from the Reserve Bank (RBA) later today. In the US, all three major bourses were higher: the S&amp...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer. Peter Milios: I'm Peter Milios from the Finance News Network, and today we're talking with Immutep (ASX:IMM)....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.2% to 8,135.1 points. Four ASX shares that are failing to follow the market higher today are...

Good afternoon. The ASX200 has been up 0.42% at 8,134 points. The local bourse is very close to breaking its record of 8,148 set in August. The Aussie market has so far shrugged of a second assassination attempt on former President Trump...